Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma

Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has facilitated progress in treatment of refractory/relapsed diffuse large B-cell lymphoma (DLBCL). A well-known adverse event after CAR-T therapy is cytokine release syndrome(CRS). However, the etiology and pathophysiology of CRS-related co...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki-Morita, Makiko, Arai, Yasuyuki, Ishihara, Takashi, Onishi, Tomoko, Shimo, Hanako, Nakanishi, Kayoko, Nishiyama, Yukiko, Jo, Tomoyasu, Hiramatsu, Hidefumi, Mitsuyoshi, Takaya, Mizumoto, Chisaki, Kanda, Junya, Nishikori, Momoko, Kitawaki, Toshio, Nogami, Keiji, Takaori-Kondo, Akifumi, Nagao, Miki, Adachi, Souichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327547/
https://www.ncbi.nlm.nih.gov/pubmed/35580321
http://dx.doi.org/10.1182/bloodadvances.2022007454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327547/
https://www.ncbi.nlm.nih.gov/pubmed/35580321
http://dx.doi.org/10.1182/bloodadvances.2022007454

Ejemplares similares